HBIO
NASDAQHarvard Bioscience Inc.
Website
News25/Ratings2
News · 26 weeks38-67%
2025-10-262026-04-19
Mix2690d
- SEC Filings13(50%)
- Insider6(23%)
- Other4(15%)
- Earnings3(12%)
Latest news
25 items- SECSEC Form DEFA14A filed by Harvard Bioscience Inc.DEFA14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form DEF 14A filed by Harvard Bioscience Inc.DEF 14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- INSIDERSEC Form 4 filed by Frost Mark T4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Frost Mark T4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Duke John D4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Denelsky Stephen J4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Snider William4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERChief Executive Officer Duke John D bought $25,050 worth of shares (5,000 units at $5.01), increasing direct ownership by 5% to 105,000 units (SEC Form 4)4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form 10-K filed by Harvard Bioscience Inc.10-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- PRHarvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial ResultsFourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- PRHarvard Bioscience Announces Reverse Stock SplitHarvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced that its board of directors approved the Company's 1-for-10 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.01 per share. The Reverse Split was approved by the stockholders of the Company at a special meeting held on March 6, 2026. The Reverse Split will legally take effect at 4:30 p.m. Eastern Time, on March 13, 2026. The Reverse Split is intende
- PRHarvard Bioscience to Participate in KeyBanc's Virtual Healthcare ForumHOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets' Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company's investor relations website at 2:15pm ET that day. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. About Harvard Bioscience Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable
- PRHarvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ETHOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentati
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- PRHarvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus AreasReports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter ended Decembe
- SECSEC Form EFFECT filed by Harvard Bioscience Inc.EFFECT - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form 424B3 filed by Harvard Bioscience Inc.424B3 - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form DEF 14A filed by Harvard Bioscience Inc.DEF 14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form S-3 filed by Harvard Bioscience Inc.S-3 - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)